OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press87710.17650/1818-8346-2023-18-4-163-171BASIC RESEARCHФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ В ПРАКТИЧЕСКОЙ МЕДИЦИНЕ НА СОВРЕМЕННОМ ЭТАПЕFunctional features of natural killer cells in acute myeloid leukemiaФункциональные особенности натуральных клеток-киллеров при остром миелоидном лейкозеhttps://orcid.org/0000-0002-4119-7175NikiforovaK. A.НикифороваК. А.
Russian Federation

Ksenia A. Nikiforova 

4 Novyy Zykovskiy Proezd, Moscow 125167

Ксения Александровна Никифорова

125167 Москва, Новый Зыковский пр-д, 4

nikiforovaksenya@gmail.comhttps://orcid.org/0000-0002-8490-6066GaltsevaI. V.ГальцеваИ. В.
Russian Federation

4 Novyy Zykovskiy Proezd, Moscow 125167

125167 Москва, Новый Зыковский пр-д, 4

https://orcid.org/0000-0001-6177-3566ParovichnikovaE. N.ПаровичниковаЕ. Н.
Russian Federation

4 Novyy Zykovskiy Proezd, Moscow 125167

125167 Москва, Новый Зыковский пр-д, 4

National Medical Research Center for Hematology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России091220231841631710812202308122023https://oncohematology.abvpress.ru/ongm/article/view/877

Natural killer cells are a key component of the innate immune system in the fight against tumors. However, in acute myeloid leukemia there is a decrease in the functional activity of these cells. Their activity is under constant control of one or more inhibitory receptors and depends on the balance of inhibitory receptors activation and activating receptors stimulation. This review examines the key inhibitory and activating receptors of natural killer cells and summarizes literature data describing changes in their expression in patients with acute myeloid leukemia.

Ключевым звеном врожденного иммунитета в борьбе с опухолями являются натуральные клетки-киллеры. Однако при остром миелоидном лейкозе отмечается снижение функциональной активности этих клеток. Их активность находится под постоянным контролем одного или нескольких ингибирующих рецепторов и зависит от баланса активации этих ингибирующих и стимуляции активирующих рецепторов. В настоящем обзоре рассмотрены ключевые ингибирующие и активирующие рецепторы натуральных клеток-киллеров и обобщены данные литературы, описывающие изменение их экспрессии у пациентов с острым миелоидным лейкозом.

natural killer cellsacute myeloid leukemiaflow cytometryactivating receptorinhibitory receptorнатуральные клетки-киллерыострый миелоидный лейкозпроточная цитометрияактивирующий рецепторингибирующий рецепторCostello R.T., Fauriat C., Sivori S. et al. NK cells: innate immunity against hematological malignancies? Trends Immunol 2004;25(6):328–33. DOI: 10.1016/j.it.2004.04.005Abel A.M., Yang C., Thakar M.S. et al. Natural killer cells: development, maturation, and clinical utilization. Front Immunol 2018;9:1869. DOI: 10.3389/fimmu.2018.01869Crinier A., Dumas P.Y., Escalière B. et al. Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia. Cell Mol Immunol 2021;18(5):1290–304. DOI: 10.1038/s41423-020-00574-8Mace E.M. Human natural killer cells: form, function, and development. J Allergy Clin Immunol 2023;151(2):371–85. DOI: 10.1016/j.jaci.2022.09.022Freud A.G., Yokohama A., Becknell B. et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006;203(4):1033–43. DOI: 10.1084/jem.20052507Farag S.S., Caligiuri M.A. Human natural killer cell development and biology. Blood Rev 2006;20(3):123–37. DOI: 10.1016/j.blre.2005.10.001Srpan K., Ambrose A., Karampatzakis A. et al. Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells. J Cell Biol 2018;217(9):3267–83. DOI: 10.1083/jcb.201712085Van Acker H.H., Capsomidis A., Smits E.L. et al. CD56 in the immune system: more than a marker for cytotoxicity? Front Immunol 2017;8:892. DOI: 10.3389/fimmu.2017.00892Ziegler S., Weiss E., Schmitt A.L. et al. CD56 is a pathogen recognition receptor on human natural killer cells. Sci Rep 2017;7(1):6138. DOI: 10.1038/s41598-017-06238-4Gunesch J.T., Dixon A.L., Ebrahim T.A. et al. CD56 regulates human NK cell cytotoxicity through Pyk2. Elife 2020;9:e57346. DOI: 10.7554/eLife.57346Picard L.K., Claus M., Fasbender F. et al. Human NK cells responses are enhanced by CD56 engagement. Eur J Immunol 2022;52(9):1441–51. DOI: 10.1002/eji.202249868Chretien A.S., Fauriat C., Orlanducci F. et al. Natural killer defective maturation is associated with adverse clinical outcome in patients with acute myeloid leukemia. Front Immunol 2017;8:573. DOI: 10.3389/fimmu.2017.00573Wilk A.J., Blish C.A. Diversification of human NK cells: lessons from deep profiling. J Leukoc Biol 2018;103(4):629–41. DOI: 10.1002/JLB.6RI0917-390RMüller-Durovic B., Grählert J., Devine O.P. et al. CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age. Aging (Albany NY) 2019;11(2):724–40. DOI: 10.18632/aging.101774Mavilio D., Lombardo G., Benjamin J. et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 2005;102(8):2886–91. DOI: 10.1073/pnas.0409872102Caduff N., McHugh D., Rieble L. et al. KSHV infection drives poorly cytotoxic CD56-negative natural killer cell differentiation in vivo upon KSHV/EBV dual infection. Cell Rep 2021;35(5):109056. DOI: 10.1016/j.celrep.2021.109056Gayoso I., Sanchez-Correa B., Campos C. et al. Immunosenescence of human natural killer cells. J Innate Immun 2011;3(4):337–43. DOI: 10.1159/000328005Campos C., Pera A., Sanchez-Correa B. et al. Effect of age and CMV on NK cell subpopulations. Exp Gerontol 2014;54:130–7. DOI: 10.1016/j.exger.2014.01.008Hazeldine J., Lord J.M. The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev 2013;12(4):1069–78. DOI: 10.1016/j.arr.2013.04.003Fauriat C., Just-Landi S., Mallet F. et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007;109(1):323–30. DOI: 10.1182/blood-2005-08-027979Szczepanski M.J., Szajnik M., Welsh A. et al. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother 2010;59(1):73–9. DOI: 10.1007/s00262-009-0724-5Lichtenegger F.S., Lorenz R., Gellhaus K. et al. Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML. Leuk Res 2014;38(8):964–9. DOI: 10.1016/j.leukres.2014.05.014Chretien A.S., Granjeaud S., Gondois-Rey F. et al. Increased NK cell maturation in patients with acute myeloid leukemia. Front Immunol 2015;6:564. DOI: 10.3389/fimmu.2015.00564Rey J., Fauriat C., Kochbati E. et al. Kinetics of cytotoxic lymphocytes reconstitution after induction chemotherapy in elderly AML patients reveals progressive recovery of normal phenotypic and functional features in NK cells. Front Immunol 2017;8:64. DOI: 10.3389/fimmu.2017.00064Aggarwal N., Swerdlow S.H., TenEyck S.P. et al. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes. Cytometry B Clin Cytom 2016;90(4):349–57. DOI: 10.1002/cyto.b.21349Sanchez C.J., Le Treut T., Boehrer A. et al. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol Immunother 2011;60(1):1–13. DOI: 10.1007/s00262-010-0898-xVerheyden S., Bernier M., Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 2004;18(12):2002–7. DOI: 10.1038/sj.leu.2403525Verheyden S., Demanet C. Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions. Leukemia 2006;20(8):1437–8. DOI: 10.1038/sj.leu.2404279Ruggeri L., Mancusi A., Capanni M. et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110(1):433–40. DOI: 10.1182/blood-2006-07-038687Curti A., Ruggeri L., D’Addio A. et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011;118(12):3273–9. DOI: 10.1182/blood-2011-01-329508Konova Z.V., Parovichnikova E.N., Galtseva I.V. et al. Influence of killer immunoglobulin-like receptor genes of natural killer cells and their HLA ligands on the results of allogeneic hematopoietic stem cells transplantation. Gematologiya i transfuziologiya = Hematology and Transfusiology 2022;67(4):551–69. (In Russ.). DOI: 10.35754/0234-5730-2022-67-4-551-569Конова З.В., Паровичникова Е.Н., Гальцева И.В. и др. Влияние генов киллерных иммуноглобулинподобных рецепторов натуральных киллерных клеток и их HLA-лигандов на результаты трансплантации аллогенных гемопоэтических стволовых клеток. Гематология и трансфузиология 2022;67(4):551–69. DOI: 10.35754/0234-5730-2022-67-4-551-569Ruggeri L., Mancusi A., Capanni M. et al. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005;17(2):211–7. DOI: 10.1016/j.coi.2005.01.007Borrego F., Masilamani M., Marusina A.I. et al. The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance. Immunol Res 2006;35(3):263–78. DOI: 10.1385/IR:35:3:263Nguyen S., Dhedin N., Vernant J.P. et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005;105(10):4135–42. DOI: 10.1182/blood-2004-10-4113Stringaris K., Sekine T., Khoder A. et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 2014;99(5):836–47. DOI: 10.3324/haematol.2013.087536Wu Z., Zhang H., Wu M. et al. Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia. Biomed Pharmacother 2021;137:111299. DOI: 10.1016/j.biopha.2021.111299Raulet D.H., Gasser S., Gowen B.G. et al. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013;31: 413–41. DOI: 10.1146/annurev-immunol-032712-095951Horton N.C., Mathew P.A. NKp44 and natural cytotoxicity receptors as damage-associated molecular pattern recognition receptors. Front Immunol 2015;6:31. DOI: 10.3389/fimmu.2015.00031Koch J., Steinle A., Watzl C. et al. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 2013;34(4):182–91. DOI: 10.1016/j.it.2013.01.003Costello R.T., Sivori S., Marcenaro E. et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002;99(10):3661–7. DOI: 10.1182/blood.v99.10.3661Sanchez-Correa B., Morgado S., Gayoso I. et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 2011;60(8):195–205. DOI: 10.1007/s00262-011-1050-2Sivori S., Pende D., Bottino C. et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999;29(5):1656–66. DOI: 10.1002/(SICI)1521-4141(199905)29:053.0.CO;2-1Pende D., Parolini S., Pessino A. et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190(10):1505–16. DOI: 10.1084/jem.190.10.1505Khaznadar Z., Boissel N., Agaugué S. et al. Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion. J Immunol 2015;195(6):2580–90. DOI: 10.4049/jimmunol.1500262Chretien A.S., Fauriat C., Orlanducci F. et al. NKp30 expression s a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. Oncotarget 2017;8(30):49548–63. DOI: 10.18632/oncotarget.17747Chretien A.S., Devillier R., Fauriat C. et al. NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. Oncoimmunology 2017;6(12):e1307491. DOI: 10.1080/2162402X.2017.1307491Sanchez-Correa B., Gayoso I., Bergua J.M. et al. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 2012;90(1):109–15. DOI: 10.1038/icb.2011.15Bottino C., Castriconi R., Pende D. et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003;198(4):557–67. DOI: 10.1084/jem.20030788Pende D., Bottino C., Castriconi R. et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol 2005;42(4):463–9. DOI: 10.1016/j.molimm.2004.07.028Almeida-Oliveira A., Smith-Carvalho M., Porto L.C. et al. Agerelated changes in natural killer cell receptors from childhood through old age. Hum Immunol 2011;72(4):319–29. DOI: 10.1016/j.humimm.2011.01.009Myers J.A., Schirm D., Bendzick L. et al. Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion. JCI Insight 2022;7(15):e150079. DOI: 10.1172/jci.insight.150079Pende D., Spaggiari G.M., Marcenaro S. et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005;105(5):2066–73. DOI: 10.1182/blood-2004-09-3548Nowbakht P., Ionescu M.C., Rohner A. et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005;105(9):3615–22. DOI: 10.1182/blood-2004-07-2585Salih H.R., Antropius H., Gieseke F. et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102(4):1389–96. DOI: 10.1182/blood-2003-01-0019Paczulla A.M., Rothfelder K., Raffel S. et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature 2019;572(7768):254–9. DOI: 10.1038/s41586-019-1410-1Mastaglio S., Wong E., Perera T. et al. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Blood Adv 2018;2(4):335–46. DOI: 10.1182/bloodadvances.2017015230Miller J.S., Soignier Y., Panoskaltsis-Mortari A. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105(8):3051–7. DOI: 0.1182/blood-2004-07-2974Rubnitz J.E., Inaba H., Ribeiro R.C. et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010;28(6):955. DOI: 10.1200/JCO.2009.24.4590Shaffer B.C., Le Luduec J.B., Forlenza C. et al. Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016;22(4):705–9. DOI: 10.1016/j.bbmt.2015.12.028Liu E., Marin D., Banerjee P. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 2020;382(6):545–53. DOI: 10.1056/NEJMoa1910607Chu J., Deng Y., Benson D.M. et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014;8(4):917–27. DOI: 10.1038/leu.2013.279